Conference Reports for NATAP

Back

Paris Special EASL Meeting Pais, France September 23-24, 2016     Barriers To HCV Treatment in Methadone Users / Philadelphia Study-Temple University - (09/27/16)   Meta-Analysis of the Real-World Effectiveness of Ombitasvir/Paritaprevir ritonavir ± Dasabuvir ± Ribavirin in Patients With HCV Genotype 1 or 4 Infection - (09/26/16)   Ribavirin Management in HCV Genotype 4 Patients Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in the Phase 3 AGATE-I Study - (09/26/16)   Analysis of Baseline Variants in GT1a-Infected Pati ents Treated With 3D With and Without RBV, and Cirrhotic GT1a Patients Treated With 3D Plus RBV for 12 or 24 Weeks - (09/26/16)   GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Patients With Genotype 1a Chronic Hepatitis C Virus Infection Without Cirrhosis - (09/26/16)   GARNET: High SVR Rates Following 8-Week Treatment With Ombitasvir/ Paritaprevir/Ritonavir + Dasabuvir in Patients With HCV Genotype 1b Infection - (09/26/16)   Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV - (09/26/16)   Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection - (09/26/16)   AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C - (09/26/16)